PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...

The company was testing its therapy, cibotercept, in patients with pulmonary arterial hypertension (PAH) - a rare disease ...

Whether you’re a senior in high school or a senior-living resident, you’ve likely heard of Viagra (sildenafil) — the original ...

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...

to treat pulmonary arterial hypertension (PAH) in the adult population. The therapy is used along with other PAH medications ...

Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said Wednesday ...

Cibotercept is under clinical development by Keros Therapeutics and currently in Phase II for Pulmonary Arterial Hypertension.

ABU DHABI - The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has introduced a groundbreaking medication for patients with Pulmonary Arterial ...

The Department of Health—Abu Dhabi (DoH)—has granted early access to a groundbreaking medication for patients with pulmonary arterial hypertension, making the emirate the first in the region ...

NEW YORK, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros ...

Patients continued taking their medications for pulmonary arterial hypertension (PAH) when symptoms appeared to improve, according to a new survey. Professional guidelines say that when pulmonary ...